This is a summary of the European public assessment report (EPAR) for Zinforo. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zinforo.
For practical information about using Zinforo, patients should read the package leaflet or contact their doctor or pharmacist.
Zinforo : EPAR - Summary for the public (PDF/79.57 KB)
First published: 18/09/2012
Last updated: 27/03/2017
Zinforo : EPAR - Risk-management-plan summary (PDF/272.79 KB)
First published: 27/03/2018
Last updated: 27/03/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Pfizer Ireland Pharmaceuticals
|Date of issue of marketing authorisation valid throughout the European Union||
04/07/2019 Zinforo - EMEA/H/C/002252 - II/0038
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Antibacterials for systemic use
Zinforo is indicated for the treatment of the following infections in adults and children from the age of 2 months:
- Complicated skin and soft tissue infections (cSSTI);
- Community-acquired pneumonia (CAP).
Consideration should be given to official guidance on the appropriate use of antibacterial agents.